NASDAQ: JANX - Janux Therapeutics, Inc.

Altı ay boyunca karlılık: -41.41%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Janux Therapeutics, Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.

daha fazla ayrıntı
The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2021-06-11
ISIN US47103J1051
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.januxrx.com
Цена ао 30.12
Günlük fiyat değişimi: 0% (28.95)
Haftalık fiyat değişimi: +21.69% (23.79)
Aylık fiyat değişimi: -5.64% (30.68)
3 ayda fiyat değişimi: -36.16% (45.35)
Altı ayda fiyat değişimi: -41.41% (49.41)
Yıllık fiyat değişimi: -42.73% (50.55)
3 yılda fiyat değişimi: +105.9% (14.06)
Yılbaşından bu yana fiyat değişimi: -48.99% (56.75)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 271.8 1
P/BV 2.81 6
P/E 0 0
EV/EBITDA -24.99 0
Toplam: 1.5

Yeterlik

İsim Anlam Seviye
ROA, % -9.57 0
ROE, % -10.09 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.2329 10
Toplam: 8.4

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 2686.32 10
karlılık Ebitda, % 1397.68 10
karlılık EPS, % 204.67 10
Toplam: 10
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
RA Capital Management, L.P. 9165652 17.74
FMR, LLC 4671213 9.04
BVF Inc. 4579818 8.87
Orbimed Advisors LLC. 3317927 6.42
Citadel Advisors Llc 3120205 6.04
Janus Henderson Group PLC 1931477 3.74
Blackrock Inc. 1762101 3.41
Adage Capital Partners GP L.L.C. 1355475 2.62
Vanguard Group Inc 979483 1.9
Geode Capital Management, LLC 408190 0.79

ETFPaylaşmak, %Yıllık karlılık, %Temettüler, %
Future Tech ETF 0.25252 426.34 0.8416
Principal Healthcare Innovators ETF 0.25252 618.5 0.8416
0.25522.420.84



Süpervizör İş unvanı Ödeme Doğum yılı
Dr. David Alan Campbell Ph.D. President, CEO & Director 1.04M 1960 (65 yıllar)
Mr. Byron Robinson J.D., Ph.D. Chief Strategy Officer 723k 1965 (60 yıllar)
Mr. Charles M. Winter Chief Technical Officer 590.4k 1969 (56 yıllar)
Mr. James Pennington General Counsel N/A
Ms. Brenda Van Vreeswyk Head of Human Resources N/A
Mr. Andy Hollman Meyer Chief Business Officer N/A 1984 (41 yıl)
Dr. Tommy Diraimondo Ph.D. Chief Scientific Officer N/A 1986 (39 yıllar)
Mr. Matt Whitmire Vice President of Finance
Ms. Maria Dobek Principal Accounting Officer & VP of Accounting 1989 (36 yıllar)

Adres: United States, La Jolla. CA, 11099 North Torrey Pines Road - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.januxrx.com